SCHEMBL7459151

SCHEMBL7459151

O=c1cc(CCl)c2cc(Cl)c(O)cc2o1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 8/20 0.79
TDP1 Q9NUW8 1/20 0.61
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
ERAP1 Q9NZ08 1/20 0.57
AKR1B1 P15121 2/20 0.53
PON1 P27169 1/20 0.49
DYRK1A Q13627 1/20 0.49
LMNA P02545 1/20 0.49
PPARG P37231 1/20 0.49
NCOA2 Q15596 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
NCOR2 Q9Y618 1/20 0.49
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 5/20 0.46
HPGD P15428 4/20 0.46
HSD17B10 Q99714 3/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8702627 0.88 MCL1 (1.00) MCL1TDP1MEN1KMT2AAKR1B1
SCHEMBL12433409 0.83 MCL1 (0.57) MCL1TDP1MEN1KMT2AERAP1
SCHEMBL15082515 0.83 MCL1 (0.61) MCL1TDP1MEN1KMT2AERAP1
SCHEMBL9277841 0.83 MCL1 (0.77) MCL1MEN1KMT2AAKR1B1PON1
SCHEMBL7450481 0.83 MCL1 (0.77) MCL1TDP1MEN1KMT2AERAP1
SCHEMBL3091159 0.82 HSD17B3 (0.63) MCL1TDP1MEN1KMT2AERAP1
SCHEMBL15084993 0.80 MEN1 (0.58) MCL1TDP1MEN1KMT2AERAP1
SCHEMBL15082520 0.80 MCL1 (0.57) MCL1TDP1MEN1KMT2AERAP1
SCHEMBL7459816 0.79 MCL1 (0.56) MCL1TDP1MEN1KMT2AERAP1
SCHEMBL14473552 0.79 TDP1 (0.56) MCL1TDP1MEN1KMT2AERAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6472541-B2 HALOGENATED- COUMARIN, QUINOLINE-2-ONE, XANTHENE, THIOXANTHENE, SELENOXANTHENEN, OR ANTHRACENE DERIVATIVES; IRRADIATING TO CONTROL THE RELEASE OF THE SOMPOUND SPATIALLY AND TEMPORALLY TO PROBE ITS BIOLOGICAL EFFECTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2002-10-29 US disclosed
EP-1151350-A4 PROTECTING GROUPS WITH INCREASED PHOTOSENSITIVITIES UNIV CALIFORNIA (US) 2002-08-21 EP disclosed
US-20020016472-A1 PROTECTING GROUPS WITH INCREASED PHOTOSENSITIVITIES REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE 2002-02-07 US disclosed
EP-1151350-A1 PROTECTING GROUPS WITH INCREASED PHOTOSENSITIVITIES The Regents of the University of California (US) 2001-11-07 EP disclosed
WO-2000031588-A1 PROTECTING GROUPS WITH INCREASED PHOTOSENSITIVITIES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016472-A1 PROTECTING GROUPS WITH INCREASED PHOTOSENSITIVITIES ERCC4, XPA, GPX4 MCL1 1400/4885TDP1 793/4885MEN1 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.